사이넥스

공인인증서가 없어도 법인 및 연구비 (신용)카드로 결제가 가능합니다.

문의: contact@techforum.co.kr   전화: 070-7169-5396   www.techforum.co.kr


Hemostat Market in Korea 2020

판 매 가
2750000
제조사
사이넥스
구성
규격
144쪽 (A4, 영문, PDF, VAT포함)
부록
본 도서는 'PDF파일' 로 제공됩니다. (종이책자는 제공되지 않습니다.)
발간일
2020-04
수량

본 도서는 'PDF파일' 로 제공됩니다.

 

In 2018, the local hemostatic market in Korea is estimated to have reached US$*** million based on initial supply price and US$*** million based on end user (medical institution) purchase price.

Korean hemostatic market is expected to grow at an average annual rate of ***% over the five years from 2019. In 2023, the market is expected to reach US$***million based on the initial supply price and US$*** million based on the final purchase price of medical institution users.

In 2018, about US$ *** million (***%) out of US$*** Million paid by medical institutions was reimbursed by the National Health Insurance Service (NHIS), whereas it is estimated that the remaining US$*** million (***%) was paid by patients themselves. This is because NHIS does not pay the full price for local hemostats used in surgery, and the difference must be paid by the patient out-of-pocket.

In 2018, the total reimbursement of local hemostats by NHIS was US$*** million. The surgical hemostats pharmaceuticals reimbursement was US$*** million (***%), surgical hemostats medical device was US$*** million (***%), and post vascular intervention surgeries medical device reimbursement was about US$*** million (***%). In 2018, health insurance benefits reimbursement of local hemostats grew by ***% to US$*** million from the previous year. In 2016, the reimbursement was US$*** million, and it grew at an annual rate of ***% over the next two years.

In 2019, the local hemostat market is expected to grow ***% from 2018, reaching around US$*** million based on initial supply price, and US$*** million based on medical institution purchase prices. Of these, the health insurance reimbursement component is estimated to be US$*** million.

 

Based on the reimbursement of surgical hemostats by department category in 2018, neurosurgery was US$***million, the highest portion (***%) of the total reimbursement of US$*** million, followed by general surgery US$***million(***%) and thoracic surgery US$*** million(***%).

Based on the reimbursement of surgical hemostats by end user category in 2018, university hospitals were US$*** million, the highest portion (***%) of the total reimbursement of US$*** million, followed by general hospitals US$***million(***%) and hospitals US$*** million(***%) (see footnote to Fig.10 for institutional descriptors).

 

In 2018, *** manufacturers / importers registered about *** products with the National Health Insurance Service. Based on the listed product codes in the``Therapeutic products Reimbursement/Non-Reimbursement List and Maximum Cap Price Table'', the11 major suppliers in the local hemostatic market are Baxter, Hyundai Pharmaceutical, GC Pharma, Johnson& Johnson Medical, DalimTissen, Hanmi Healthcare, Samyang Biopharm, Bard Korea, Curesys, Nano Pharm, and SK Plasma. The top three suppliers (Baxter, Hyundai Pharmaceutical and GC Pharma) had ***% of the total market, and the remaining *** suppliers account for ***% of the market. Of the top three companies, Baxter (with Floseal, Tiseal and HemoPatch) accounted for ***% of the market, Hyundai (with Tachosil) ***%, and GC Pharma (with Greenplast) ***% of the market.

Product composition can be classified into oxidized regenerated cellulose (ORC), gelatin, collagen, mixed ingredients and materials, and miscellaneous constituents. Accordingly, hemostat suppliers distribute various products, consisting of different product forms and ingredients, according to the needs of customers, using different sales and marketing strategies.

In the 1990s, AviteneTM and SURGICEL®products paved the way for the foundation of the Korean hemostatic drug products market. Since 2017, the number of suppliers and diversification of products continues, as the NHI system expanded the reimbursement criteria for local hemostatic approved as medical devices. The local hemostat market has grown continuously due to health insurance coverage expansion, and it is expected that this will continue.

Korean hemostat market is expected to grow at an annual average of ***% over the next five years, driven by increases in the aging population, the number of surgical procedures, the number of endoscopic and robotic surgical procedures, the number of cancer patients, the number of trauma centers, and the number of foreign patients. On the other hand, the health insurance pricing decision method based on the mechanism of action, shape, size, etc., of the product, is expected to suppress the distribution of hemostats with various materials and effects. In addition, local hemostatic agents are classified into Diagnostic Related Group (DRG) and new Diagnostic Related Group (nDRG) products, and government policy in relation to expanding the application of DRG and nDRG will act to restrain the use of hemostats and market growth.

The preferences for hemostatic products have accumulated over a long period of time, thus, an abrupt change in practice and utilization is unlikely in the short term. However, in order to provide quality medical services, there still remains high interest in the use of hemostats, and the potential demand and unmet need for hemostats with proven effectiveness and safety will continue. Therefore, there are still opportunities for growth for new products that fulfil the requirements of user friendliness, improved preparation time, cost and effectiveness.

 

 -CONTENTS-

GLOSSARYOF TERMS,ABBREVIATIONS, AND ACRONYMS


CH 1. INTRODUCTION
1.1 Purpose
1.2 Utilization of Benefits
1.3 Scope
1.4 Market Segementation
1.5 Definition
1.6 Research Methods
1.6.1 Secondary Research
1.6.2 Primary Research
1.7 Analysis and Estimateion Methods
1.7.1 Market Size Price Standard by Data Source
1.7.2 Exchange Rate
1.7.3 Market Size Estimation Methods
1.7.3.1 Reimbursement Size Estimation Methods

CH 2. EXECUTIVE SUMMARY

CH 3. MARKET OVERVIEW
3.1 Total Market
3.1.1 5-Year Forecast
3.2 Use Volume of Hemostats by Medical Institutions
3.2.1 Total Hemostats Product Market
3.2.2 Surgeries, Hemostats Product Market
3.2.2.1 Hemostats Product Market, By Medical Department
3.2.2.2 Hemostats Product Market, By End User Type
3.2.3 Postoperative Vascular Intervention Hemostats Product Marke

CH 4. MAJOR SUPPLIERS STATUS
4.1 Baxter
4.2 Hyundai Pharm
4.3 GC Pharma
4.4 Johnson & Johnson Medical Korea Ltd
4.5 Dalim Tissen Co.,Ltd
4.6 Hanmi Healthcare Inc
4.7 Samyang Biopharm
4.8 Bard Korea Ltd
4.9 Curesys
4.10 Nano Pharm
4.11 SK Plasma Co., Ltd.

CH 5. MARKET DYNAMICS
5.1 Counter Healthcare Key Indicators
5.1.1 Historical Overview and Prospect of Market Development
5.1.2 Historical Overview of Payment Environment
5.1.3 Number of Medical Institutions in Korea
5.1.4 Reimbursement and Non-Reimbursement Classifications of Hemostats
5.2 Recent trends in key indicators of Hemostats Market Size
5.2.1 Aging Population
5.2.2 Number of Surgical Procedures
5.2.3 Number of Endoscopic Surgery
5.2.4 Robotic Surgery
5.2.5 Number of Cancer Patients
5.2.6 Trauma Center
5.2.7 Number of Foreign Patients
5.3 Market Drivers
5.3.1 Main Indicator
5.3.2 Supply
5.4 Opportunity
5.4.1 Increasing Demand due to Increase in Number of Surgeries
5.4.2 Coverage Expansion of National Health Insurance Policy
5.4.3 Hemostats with Innovative Features
5.4.4 Clinical Study on Hemostats Treatment Technology
5.5 Threat
5.5.1 Revaluation Reimbursement Prices
5.5.2 Expansion of Diagnosis Related Group(DRG) and New Diagnosis Related Group(nDRG)
5.6 Unmet Needs

 

-TABLES-

[Table 1] Hemostats Classfication by MFDS
[Table 2] Korean Hemostats Supply Volume in Korea (2014-2018) (Unit: US$1,000, %)
[Table 3] Korean Hemostats Market Volume Forecast (2018-2023) (Unit: US$ 1,000, %)
[Table 4] Reimbursement Volume by Hemostats Product Category (2016-2018) (Unit: EA, US$1,000)
[Table 5] Reimbursement Volume by Surgical Hemostats (2016-2018) (Unit: EA, US$1,000)
[Table 6] Quarterly Reimbursement Volume of Surgical Hemostats, Classified as Medical Device (Unit: EA, US$1,000)
[Table 7] Reimbursement Volume of Surgical Hemostats, By Medical Department (2016-2018) (Unit: EA, US$1,000)
[Table 8] Hemostats Sales Prospects by Major Surgical DepartmentHemostats Sales Prospects by Major Surgical Department
[Table 9] Surgical Hemostats Market, by End User Type (2016-2018) (Unit: EA, US$1,000)
[Table 10] Reimbursement Volume by Postoperative Vascular Intervention Hemostats (2016-2018) (Unit: EA, US$1,000)
[Table 11] Manufacturer/Importer and Distributor, by Major Brands
[Table 12] Major Brands Suppliers Market Share Estimation (2018) (Unit: %)
[Table 13] Product Forms Supply Status, by Major Companies (2019.12 Basis)
[Table 14] Major Ingredients and Features, by Product Forms1
[Table 15] Product Ingredients Supply Status, by Major Companies (December 2019)
[Table 16] Major Ingredients Related Product, by Major Surgeries and Bleeding Patterns
[Table 17] Baxter Main Product - Tisseel
[Table 18] Baxter Main Product - Floseal
[Table 19] Baxter Main Product – Hemo Patch
[Table 20] Hyundai Pharm Main Product – Tachosil®
[Table 21] GC Pharma Main Product – Greenplast-Q Prefilled Syringe KIT®
[Table 22] Johnson & Johnson Korea Ltd Main Product– SURGICEL®
[Table 23] Johnson & Johnson Korea Ltd Main Product– EViCEL®
[Table 24] Johnson & Johnson Korea Ltd Main Product– SPONGOSTAN®
[Table 25] Dalim Tissen Co., Ltd Main Product - Collastat
[Table 26] Hanmi Healthcare Inc. Main Product– Kollagen resorb
[Table 27] Samyang Biopharmaceuticals Main Product – SurgiGuard®
[Table 28] Samyang Biopharmaceuticals Main Product – Q-GuardTM
[Table 29] Bard Korea Ltd Main Product – AviteneTM
[Table 30] Bard Korea Ltd Main Product – AristaTM
[Table 31] Curesys Main Product - NOVACOL Pad
[Table 32] Curesys Main Product - NOVACOL Fibrillar®
[Table 33] Curesys Main Product - Equitamp®
[Table 34] Curesys Main Product – Cutanplast sponge
[Table 35] Nano Pharm Corp. Main Product– Avitene Web
[Table 36] SK Plasma Co., Ltd. Main Product - Beriplast® P Combi-Set
[Table 37] Number of Medical Institutions in Korea (2019)* (Unit: Case, %)
[Table 38] Reimbursement and Non-Reimbursement Classifications of Hemostats
[Table 39] Korean Population and Elderly Population of Age 65 or Over (Unit: Number of people, %)
[Table 40] Number of National Health Insurance Claims for Surgical Procedures (2014-2018) (Unit: Case, %)
[Table 41] Annual Number of Major Surgical Procedures (2014-2018) (Unit: Case, %)
[Table 42] Endoscopic Surgery Status in Korea (2014-2018) (Unit: Number of patients, US$1,000)
[Table 43] Robotic Surgery Act Code, Term and Names 117116
[Table 44] Number of Robotic Surgery Procedures (2005-2014) (Unit: EA)
[Table 45] Number of Cancer Patients (2013-2018) (Unit: Number of patients, %)
[Table 46] Number of Trauma Centers (2014-2018) (Unit: Case, %)
[Table 47] Trauma Center Details
[Table 48] Foreign Patient Status (2014-2018) (Unit: Number of patients, %)
[Table 49] Foreign Patients Status by Clinical Department (2014-2018) (Unit: Number of patients, %) 124123
[Table 50] Summary of Market Drivers
[Table 51] Number of Hemostats Listed for Reimbursement (Unit: Case, %) 128127
[Table 52] Hemostats Clinical Trial Approvals (2016-2020) (January 2020)
[Table 53] Absorbable Hemostats Products Classification and Maximum Cap Price Reference
[Table 54] Diagnostic Related Group Claims (2014-2018) (Unit: EA, US$1,000)

 

-FIGURES-

[Fig 1] Hemostats Initial Supply Volume in Korea (unit: US$1,000)
[Fig 2] Hemostats Supply Volume in Korea (2014-2018) (unit: US$1,000)
[Fig 3] Korean Hemostats Market Sales Forecast (2018-2023) (Unit: US$ 1,000)
[Fig 4] Use Volume of Hemostats by Medical Institutions (2018)
[Fig 5] Use Volume of Hemostats Market Sales Forecast of Medical Institutions (2019-2023)
[Fig 6] Reimbursement Volume by Hemostats Product Category (2016-2018)
[Fig 7] Reimbursement Volume by Surgical Hemostats Product Category (2016-2018)
[Fig 8] Surgical Hemostats Market, By Medical Department (2018)
[Fig 9] Surgical Hemostats Market, By Medical Department (2016-2018)
[Fig 10] Surgical Hemostats Market, By End User Type (2018)
[Fig 11] Surgical Hemostats Market, By End User Type (2016-2018)
[Fig 12] Reimbursement Volume by Postoperative Vascular Intervention Hemostats (2016-2018)
[Fig 13] Sales Volume of Korean Hemostats Distributors Market Share Estimation (2018)
[Fig 14] Elderly Age 65 or Over Populations (2005-2014) (Unit: million)
[Fig 15] Number of National Health Insurance Claims for Surgical Procedures (2014-2018) (Unit: Case)
[Fig 16] Number of Endoscopic Surgery Procedures (2014-2018)
[Fig 17] Number of Robotic Surgery Procedures(2005-2014) (Unit: Case)
[Fig 18] Number of Foreign Patients (2014-2018)
[Fig 19] Number of Reimbursement Claim Numbers and Reimubrsement Size of Diagnosis Related Group (DRG) Procedures (Unit: Each Case, US$ 1,000)
[Fig 20] Unmet Needs of Korean Hemostats Market

 

-MENTIONED COMPANIES-Baxter
Hyundai pharm
Green Cross Corp
Johnson& Johnson Medical
DalimTissen
Hanmi Healthcare
Samyang Biopharm
Bard Korea
Curesys
Nano Pharm
SK Plasma
Cardical Health Korea
Abbott Korea Limited
Terumo Korea Corporation Co.,LTD.


 

※ 도서상품(보고서 및 세미나북)은 비과세상품(면세대상)으로 공급가액만 결제됩니다.
※ 현금 결제시 세금계산서가 아닌 계산서가 발행됩니다.



배송정보
- 배송지역: 전국
- 배송비: 무료입니다.(도서,산간,오지 일부지역 등은 배송비가 추가될 수있습니다.)
- 본 상품의 평균 배송일은 2일입니다.(입금 확인 후)
(평균배송일이란? 동일 상품을 주문한 고객이 실제 인수한 배송일의 평균을 말합니다.)


카드결제 오류 해결방법
대부분 카드결제 오류 발생시 KCP기술지원팀(1544-8661)으로 연락 주시면 '결제오류'에 대한 보다 신속하고 상세한 안내(원격지원)를 받으실 수있습니다.


ARS 결제 서비스
온라인 카드 결제 시 잘 안 되실 경우 테크포럼 고객센터(070-7169-5396)로 전화 주시면 'ARS 결제 서비스'를 안내 해드립니다.
ARS 결제 서비스 절차는 아래와 같습니다.

① 'ARS 결제 서비스' 요청

② 고객님 휴대폰으로 'ARS 결제' 문자 발송

③ ARS 전화 연결

④ 카드번호, 카드유효기간(MM/YY), 법인카드는 사업자번호 / 개인카드(법인기명카드)는 생년월일, 비밀번호(앞두자리) 입력

⑤ 결제완료


계산서
- 현금결제(계좌이체, 무통장입금)건에 한해서 발행됩니다.
- 계산서가 필요하신 분은 주문시 '요구사항'란에 메모를 남겨주세요.
- 사업자등록증 사본을 이메일(contact@techforum.co.kr) 또는 팩스(070-7159-1608)로 보내주시기 바랍니다.
- 요청하신 계산서는 등록하신 메일로 발송됩니다.


거래명세서
- 거래명세서가 필요하신 분은 주문시 '요구사항'란에 메모를 남겨주세요.
- 사업자등록증 사본을 이메일(contact@techforum.co.kr) 또는 팩스(070-7159-1608)로 보내주시기 바랍니다.
- 요청하신 거래명세서는 등록하신 메일로 발송됩니다.


견적서
- 견적서가 필요하신 분은 도서 목록을 이메일(contact@techforum.co.kr) 로 보내주시기 바랍니다.
- 요청하신 견적서는 등록하신 메일로 발송됩니다.


교환/반품
- 주문하신 도서가 품절 및 절판등의 사유로 발송할 수 없을시 에는 대금을 환불해 드립니다.
- 도서의 파손이나 불량으로 인한 교환을 요청하실 경우에는 재발송하여 드립니다. (택배비 무료)
- 고객의 부주의로 인한 도서의 파손은 환불처리가 불가하오니 양해바랍니다.

상품 리뷰
No 제목 작성자 날짜 평점
상품 문의
No 제목 작성자 날짜 상태